Ding Xiaosheng, Li Xiaoyan, Yin Peng, Wang Lijun, Qi Jinlei, Liu Weiping
Department of Oncology, Beijing Tiantan Hospital, Capital Medical University, No. 119 Nansihuan West Road Fengtai District, Beijing, 100070, PR China.
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, No.52 Fucheng Road, Haidian District, Beijing, 100142, PR China.
Heliyon. 2024 Jun 19;10(12):e32996. doi: 10.1016/j.heliyon.2024.e32996. eCollection 2024 Jun 30.
The incidence of multiple myeloma (MM) has increased over time in China. Despite this increase, comprehensive and up-to-date statistics on its mortality at national and provincial scales are lacking. To bridge this gap, we used mortality data from the disease surveillance points system operated by the Chinese Center for Disease Control and Prevention. Mortality rates were standardized against the 2010 census population of China (ASMRC) and Segi's world population (ASMRW). Joinpoint regression models were used to analyze temporal trends. Our findings indicated an estimated 14,568 MM-related deaths in China. The observed crude mortality rates ASMRC, and ASMRW were 1.04, 0.80, and 0.62 per 100,000 individuals, respectively. A notable sex-related difference in mortality rates was evident, with male mortalities (8,319) surpassing female mortalities (6,249) by a factor of 1.33. Age-wise, mortality rates tended to increase after 55 years, reaching a maximum in those over 85 years (7.09 per 100,000 individuals). Provincial data revealed that the highest ASMRCs were in Zhejiang, Beijing, and Jiangxi, whereas the lowest were in Tibet, Qinghai, and Hainan. The period from 2013 to 2020 exhibited a significant increase of 58.09 % in MM mortality, with urban and rural areas exhibiting a 44.97 % and 70.94 % increase, respectively. This analysis highlights the growing mortality burden of MM across various demographics and regions, emphasizing the need for tailored disease management and preventive measures.
在中国，多发性骨髓瘤（MM）的发病率随时间推移有所上升。尽管如此，在国家和省级层面缺乏关于其死亡率的全面且最新的统计数据。为了填补这一空白，我们使用了中国疾病预防控制中心运营的疾病监测点系统的死亡率数据。死亡率根据2010年中国人口普查数据（ASMRC）和世标人口（ASMRW）进行了标准化。采用Joinpoint回归模型分析时间趋势。我们的研究结果表明，中国估计有14568例与MM相关的死亡病例。观察到的基于ASMRC和ASMRW的粗死亡率分别为每10万人1.04、0.80和0.62例。死亡率存在明显的性别差异，男性死亡率（8319例）超过女性死亡率（6249例），比例为1.33。按年龄划分，死亡率在55岁之后趋于上升，在85岁以上人群中达到最高（每10万人7.09例）。省级数据显示，ASMRC最高的是浙江、北京和江西，而最低的是西藏、青海和海南。2013年至2020年期间，MM死亡率显著上升了58.09%，城市和农村地区分别上升了44.97%和70.94%。该分析突出了MM在不同人口统计学和地区的死亡负担不断增加，强调了需要采取针对性的疾病管理和预防措施。
